IMA203 Clinical Trials
2 recruitingBiologic
Phase 11Phase 31
Showing 1–2 of 2 trials
Recruiting
Phase 3
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
Melanoma, Cutaneous Malignant
Immatics US, Inc.360 enrolled59 locationsNCT06743126
Recruiting
Phase 1
ACTengine® IMA203 Combined With mRNA-4203
Cutaneous MelanomaSynovial Sarcoma
Immatics US, Inc.15 enrolled4 locationsNCT06946225